J&J grad Seth Fischer is replacing Zook as Vivus CEO, just two months after the former AstraZeneca exec’s appointment.
Business briefs: Akorn, Bayer, Lonza, plus curbing CNS drug use
August 27, 2013
5:47 pm
Akorn expands, buying Hi-Tech Pharmacal; nursing homes miss their goal to curb antipsychotic-drug use; Bayer cancer drug gets priority review; and Lonza lays off staff
Quarterly sales fell 11% compared to the same period last year. The company plans on weathering a continued flow of patent losses with a narrower R&D focus.
Business briefs: Elan and Valeant
July 29, 2013
5:06 pm
Perrigo sweeps Elan off its feet for $8.6 billion, and Valeant is slashing 2,700 jobs.
Business briefs: Roche, WellPoint, Bayer, Takeda, Allergan
June 26, 2013
5:06 pm
A JAMA article says prostate cancer patients are getting treatments they don’t need; Roche and AstraZeneca will share safety data; WellPoint gives cost sharing a new spin; Bayer seeks to boost its oncology pipeline; Takeda announces organizational changes; and the FDA puts Allergan’s Restasis on track for generic competition.
R&D chief’s spring-cleaning sweeps through Merck labs